ClinicalTrials.gg
CompletedNCT01254344Updated Mar 22, 2017Results posted

Efficacy and Safety of Ertapenem Sodium (MK-0826) Following Colorectal Surgery in Chinese Adults (MK-0826-056)

A Phase 3 interventional study of ertapenem sodium and ceftriaxone sodium in Infection and Surgical Site Infection, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2017-03-22.

Primary conditionSurgical Wound InfectionRegistry: InfectionsReclassifiedWhy we changed it
Registry
Infections — the first condition term the registry derived for this study.
ClinicalTrials.gg
Surgical Wound Infection
Why
  1. The study's listed conditions name Surgical Wound Infection, a narrower term within Infections.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
599
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

The purpose of this study is to evaluate the efficacy and safety of ertapenem sodium compared with ceftriaxone sodium/metronidazole for the prophylaxis of surgical site infection following elective colorectal surgery in Chinese adults. This study is designed to demonstrate that ertapenem sodium is non-inferior to ceftriaxone sodium/metronidazole in this participant population.

02

Conditions studied

  • Infection
  • Surgical Site Infection

Browse trials for

Keywords

  • Colorectal surgery
03

In context

Surgical Wound Infection Reclassified

747 studies on the registry are indexed under Surgical Wound Infection; 152 are open to participants now.

This study's enrollment of 599 is above the median of 200 across 583 interventional studies indexed under Surgical Wound Infection.

Browse Surgical Wound Infection studies →

Lead sponsor

Merck Sharp & Dohme LLC is the lead sponsor of 2,169 studies on the registry; 134 are open to participants now.

Of its 505 completed or terminated interventional studies of FDA-regulated products, 372 (74%) have results posted.

Compared within Surgical Wound Infection, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Infections. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant is scheduled to undergo elective colon or colorectal surgery by

laparotomy that is scheduled in advance with adequate time prior to surgery to

complete preoperative bowel preparation.

  • Participant is a Chinese adult between the ages of more than 18 years old and

less than 81 years old.

  • Participant is highly unlikely to conceive.

Exclusion criteria

Exclusion Criteria:

  • Participant is undergoing emergency colon or colorectal surgery.
  • Participant requires a second planned colorectal surgery or other surgery requiring antibiotic prophylaxis within the 4-week follow-up period.
  • Participant is undergoing laparoscopic-assisted surgery.
  • Participant is undergoing an isolated rectal procedure.
  • Participant has a decompensated intestinal obstruction.
  • Participant has active inflammatory bowel disease involving the colon (i.e.,

ulcerative colitis or Crohn's disease).

  • Participant is scheduled to undergo an elective colorectal procedure for revision of a previous operation involving a large bowel resection.
  • Participant has a bacterial infection at the time of surgery.
  • Participant requires or is anticipated to need the administration of other (nonstudy therapy) systemic antimicrobial therapy within 1 week prior to surgery or at any time during this study.
  • Participant is anticipated to receive either antibiotic or antiseptic peritoneal lavage during the surgery.
  • Participant has a history of serious allergy, (e.g., anaphylaxis), or any serious reaction to ertapenem sodium, ceftriaxone sodium, metronidazole, penicillin, or any cephalosporin, beta(β)-lactam, or nitroimidazole agents.
  • Participant is breast feeding or plans to breast feed prior to the completion of the study period.
  • Participant has neutropenia.
  • Participant with due to an underlying disease, chronic

immunosuppressive therapy, or use of high-dose .

  • Participant has a rapidly progressive or terminal illness.
  • Participant is considered unlikely to survive through the expected 4-week study period.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
599 participants (actual)

Study arms

  • Experimental
    Ertapenem sodium 1 g

    Ertapenem sodium 1 g administered intravenously (IV) as a single dose followed by matching placebo to metronidazole administered IV as a single dose

    Drug: ertapenem sodium · Drug: placebo to metronidazole

  • Active comparator
    Ceftriaxone sodium 2 g

    Ceftriaxone sodium 2 g administered intravenously (IV) as a single dose followed by metronidazole 500 mg administered IV as a single dose

    Drug: ceftriaxone sodium · Drug: metronidazole

Interventions

  • DrugErtapenemStudies of ErtapenemErtapenem pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Ertapenem sodium 1 g administered IV as a single dose over 30 minutes within 2 hours prior to the initial surgical incision

    Also known as: MK-0826, INVANZ®

  • DrugCeftriaxoneStudies of CeftriaxoneCeftriaxone pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Ceftriaxone sodium 2 g administered IV as a single dose over 30 minutes within 2 hours prior to the initial surgical incision

    Also known as: Rocephin®

  • Drugplacebo to metronidazole

    Placebo (0.9% sodium chloride) administered IV as a single dose over 30 minutes within 2 hours prior to the initial surgical incision

  • Metronidazole 500 mg administered IV as a single dose over 30 minutes within 2 hours prior to the initial surgical incision

    Also known as: Flagyl®

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Success of Prophylaxis

    Percentage of participants who have no signs or symptoms of infection at the surgical site, do not require surgical intervention for infection, and have no need for further antimicrobial therapy

    Time frame: From study drug dose (day of surgery) up to 4 weeks post therapy

Secondary outcomes

  1. Percentage of Participants With Favorable Clinical Response

    Percentage of participants who have no signs or symptoms of infection at the surgical site and do not require surgical intervention for infection

    Time frame: 4 weeks posttreatment

07

Results

Posted Nov 16, 2012

Participant flow

Participant flow — Overall Study
MilestoneErtapenemCeftriaxone/Metronidazole
Started299300
Treated290297
Completed286281
Not completed1319
Withdrew: Adverse event25
Withdrew: Physician decision74
Withdrew: Protocol violation14
Withdrew: Withdrawal by subject36

Outcome measures

PrimaryPercentage of Participants With Success of Prophylaxis

Percentage of participants who have no signs or symptoms of infection at the surgical site, do not require surgical intervention for infection, and have no need for further antimicrobial therapy

Time frame:
From study drug dose (day of surgery) up to 4 weeks post therapy
Reported as:
Number · percentage of participants
Percentage of Participants With Success of Prophylaxis
percentage of participantsErtapenemCeftriaxone/Metronidazole
Percentage of Participants With Success of Prophylaxis90.4 (86.8 to 94.1)90.3 (86.6 to 94.0)
Statistical analysis
  • Ertapenem vs Ceftriaxone/Metronidazole · Miettinen and Nurminen · Difference in percentage of prophylaxis: 0.1 · 95% CI -5.2 to 5.5
SecondaryPercentage of Participants With Favorable Clinical Response

Percentage of participants who have no signs or symptoms of infection at the surgical site and do not require surgical intervention for infection

Time frame:
4 weeks posttreatment
Reported as:
Number · percentage of participants
Percentage of Participants With Favorable Clinical Response
percentage of participantsErtapenemCeftriaxone/Metronidazole
Percentage of Participants With Favorable Clinical Response96.8 (94.6 to 99.0)95.5 (93.0 to 98.1)
Statistical analysis
  • Ertapenem vs Ceftriaxone/Metronidazole · Miettinen and Nurminen · Difference in percentage of prophylaxis: 1.3 · 95% CI -2.2 to 5.1

Adverse events

Collected over Up to and including 28 days after last administration of study drug. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ertapenem—6/290 (2.1%)23/290 (7.9%)
Ceftriaxone/Metronidazole—14/297 (4.7%)18/297 (6.1%)
Most frequent serious events
Showing 10 of 16
Most frequent serious events
EventErtapenemCeftriaxone/Metronidazole
Anastomotic LeakInjury, poisoning and procedural complications3/2901/297
Wound DehiscenceInjury, poisoning and procedural complications0/2902/297
Intestinal ObstructionGastrointestinal disorders1/2900/297
Anastomotic FistulaInjury, poisoning and procedural complications1/2901/297
Post Procedural HaemorrhageInjury, poisoning and procedural complications1/2900/297
Cardiac ArrestCardiac disorders0/2901/297
Cardiac Failure AcuteCardiac disorders0/2901/297
VomitingGastrointestinal disorders0/2901/297
CholecystitisHepatobiliary disorders0/2901/297
Cholecystitis AcuteHepatobiliary disorders0/2901/297
Most frequent other events
Most frequent other events
EventErtapenemCeftriaxone/Metronidazole
PyrexiaGeneral disorders23/29018/297

Baseline characteristics

Age, Continuous
Age, Continuous(years)ErtapenemCeftriaxone/MetronidazoleTotal
Mean59.4 ± 11.459.1 ± 12.159.2 ± 11.8
Sex: Female, Male
Sex: Female, Male(Participants)ErtapenemCeftriaxone/MetronidazoleTotal
Female125127252
Male165170335
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Leng XS, Zhao YJ, Qiu HZ, Cao YK, Zhu WH, Shen JF, Paschke A, Dai WM, Caldwell N, Wang J. Ertapenem prophylaxis of surgical site infections in elective colorectal surgery in China: a multicentre, randomized, double-blind, active-controlled study. J Antimicrob Chemother. 2014 Dec;69(12):3379-86. doi: 10.1093/jac/dku302. Epub 2014 Aug 23. PubMed 25151205 ↗

Individual participant data

Plan to share: Yes — http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf http://engagezone.msd.com/ds_documentation.php

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2010, a primary completion of Dec 2011 and a completion of Dec 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2012, 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 3, 2010
First posted
Dec 6, 2010
Start
Dec 2010
Primary completionActual
Dec 2011
CompletionActual
Dec 2011
Results first posted
Nov 16, 2012
Last update
Mar 22, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 22, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01254344
Responsible party
Sponsor
First posted
Dec 6, 2010
Start date
Dec 2010
Primary completion
Dec 2011
Completion
Dec 2011
Results posted
Nov 16, 2012
Last update
Mar 22, 2017

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ertapenem

Start the discussion